In another study, although the role and safety of PCSK9-mAbs, including evolocumab and alirocumab, were discussed, the patients with FH were controversial because the data extracted by the authors did not exclude the non-FH patients included in the clinical study [10]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.